This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page
AboutAbout  CRESEMBA®Invasive fungal infections and risk factorsMeet CRESEMBA ®CRESEMBA® patient profilesVirtual Patient ExperienceEfficacyEfficacyInvasive AspergillosisMucormycosis

Menu

Close

LabelDosingDosingDosingSafety ProfileSafety & TolerabilitySafety ProfileEmerging PopulationsEmerging PopulationsICUInvasive fungal infections in the ICUInvasive fungal infections and influenza

Invasive fungal infections in solid organ transplant recipients

Invasive fungal infections and chronic obstructive pulmonary disease

Invasive fungal infections and COVID-19 (CAPA/CAM)Support & ResourcesResourcesKOL VideosNational/Regional GuidelinesECIL-6 Guidelines
ESCMID
ID Society of AmericaVideos
MaterialsSupport & Resources

Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.

Meet CRESEMBA® 
(isavuconazole)

CRESEMBA® (isavuconazole) is indicated in adults for the treatment of invasive aspergillosis and mucormycosis in patients for whom amphotericin B is inappropriate.1

Choosing an appropriate antifungal drug can be difficult for a variety of reasons, and considerations may include:2-4


Why choose CRESEMBA®?CRESEMBA® is the only azole approved for both invasive aspergillosis and mucormycosis (for whom amphotericin B is inappropriate) and it is endorsed by guidelines1,5–12
  • CRESEMBA® may be used for early targeted therapy while awaiting pathogen confirmation from specific diagnostic tests. Once results become available, therapy should be adjusted accordingly1
  • Because CRESEMBA® may be prescribed while awaiting test results, you can act quickly when you suspect invasive aspergillosis or mucormycosis1,a
a. CRESEMBA® is indicated in adults for the treatment of invasive aspergillosis and mucormycosis in patients for whom amphotericin B is inappropriate.1CRESEMBA® is as efficacious as the standard of care in both invasive aspergillosis and mucormycosis13,14
  • In the SECURE trial (invasive aspergillosis), both survival rates and overall treatment response were comparableb with CRESEMBA® and voriconazole13
    • Survival rates (ITT): Treatment difference -1.1% (95% CI: -8.9, 6.7) p=0.744
    • Overall treatment response at end of treatment (mITT): 35% (n=50/143) vs 36% (n=47/129). Adjusted treatment difference 1.6% (95% CI: -9.3, 12.6)
  • In the VITAL trial – a single-arm, open-label trial and case control analysis – mucormycosis cases treated with CRESEMBA® as primary treatment (n=37) were matched with controls from the FungiScope Registry who received primary amphotericin B-based treatment14
    • Survival rates were similar with CRESEMBA® and amphotericin B. Weighted all-cause mortality at day 42: 33% vs 41%, p=0.595
Find out more about the efficacy of CRESEMBA® in invasive aspergillosis and mucormycosis

b. Patients were censored on the day of their last known survival statusCRESEMBA® has an improved tolerability profile vs voriconazole, with fewer drug-related adverse events13
  • In the SECURE trial, CRESEMBA® showed significant reductions in the frequency of azole-specific adverse events vs voriconazole for the treatment of invasive aspergillosis13
Scroll left to view table
AEs and treatment discontinuations in the SECURE trial13
  CRESEMBA® (n=257) Voriconazole (n=259) p value
Any TEAE 96% 98% 0.122
Drug-related TEAEs 42% 60% <0.001
TEAEs leading to discontinuation 14% 23% –
Drug-related AEs leading to discontinuation 8% 14% –

Example

Scroll left to view table
Scroll left to view table
Drug-related AEs that were reduced with CRESEMBA® vs voriconazole13
  CRESEMBA®
(n=257)		 Voriconazole (n=259) p value
Skin and subcutaneous tissue disorders 33% 42% 0.037
Eye disorders 15% 27% 0.002
Hepatobiliary disorders 9% 16% 0.016

In the VITAL trial, the AE profile of CRESEMBA® for the treatment of mucormycosis was consistent with observations from the SECURE trial. Only 16% (n=6/37) of patients with mucormycosis discontinued CRESEMBA® due to AEs14

CRESEMBA® is associated with fewer and more manageable drug-drug interactions than other azoles1,3
  • CRESEMBA® interacts with selected CYP450 pathway components to a lesser degree than other azoles1,3,15,16
  • CRESEMBA® can be administered with several medications, including  ibrutinib and some immunosuppressants, without the need to adjust its dose17
Scroll left to view table
Recommendations for the coadministration of CRESEMBA® with key medications4,c
Concomitant medication
  • Proton pump inhibitors
 
  • Statins
 
  • Warfarin
 
  • Methotrexate
 
  • Repaglinide
  • Immunosuppressants (tacrolimus, sirolimus and ciclosporin)
 
  • Short-acting opiates (alfentanyl, fentanyl)
 
  • Digoxin
 
  • Anticancer agents (other than methotrexate) including ibrutinib17
  
  • Dabigatran etexilate
 
  • Midazolam
 
  • Colchicine
Recommendation No dose adjustment for either CRESEMBA® or the concomitant medication Monitoring of concomitant medication and dose adjustment if required

Example

Scroll left to view table

Please refer to the CRESEMBA® Summary of Product Characteristics for full list of drug interactions and recommendations concerning coadministration.

c. CRESEMBA® is contraindicated in coadministration with ketoconazole, high-dose ritonavir, and strong CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long acting barbiturates, phenytoin and St. John’s wort, or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine.1 For further details and a full list of drug interactions, please consult the Summary of Product Characteristics.

CRESEMBA® may be used in patients with renal impairment and mild-to-moderate hepatic impairment without dose adustments1 Renal impairment

CRESEMBA® was specially developed to facilitate intravenous administration, and unlike other azoles it does not require potentially nephrotoxic excipients like cyclodextrin for solubilisation:1,5,6
 
  • It can be used in patients with renal dysfunction – including ESRD – without dose adjustments1
In the SECURE and VITAL trials, kidney function did not affect treatment outcomes with CRESEMBA®18,19
 
  • There was no evidence of loss of efficacy or drug-specific safety concerns in patients with renal impairment18 
  • Median length of hospital stay for patients with moderate-to-severe renal impairment was significantly shorter vs voriconazole for the treatment of invasive aspergillosis (p=0.0032)19
Mild or moderate hepatic impairment 

Risk of hepatotoxicity can be an important consideration when treating with antifungals.
 
  • No dose adjustments of CRESEMBA® is needed in patients with mild or moderate hepatic dysfunction (Child-Pugh Classes A and B)1 
  • Although elevated liver transaminases have been reported in clinical studies, they rarely required treatment discontinuation of CRESEMBA®1. Monitoring of hepatic enzymes should be considered1
    • Conversely, voriconazole has been associated with elevations in Iiver function tests and clinicaI signs of Iiver damage such as jaundice5
  • CRESEMBA® showed significantly improved hepatic tolerability vs voriconazole (frequency of hepatobiliary adverse events: 9% (n=23/257) vs 16% (n=42/259), p=0.016)13
  • CRESEMBA® has not been studied in patients with severe hepatic impairment (Child-Pugh Class C); use in these patients is not recommended unless the potential benefit outweighs the risks. These patients should be carefully monitored for potential drug toxicity1
CRESEMBA® has a simple and reliable dosing regimen, and its high oral bioavailability allows for interchangeable IV and oral dosing1,3
  • CRESEMBA® offers simple and flexible dosing to help with complicated clinical scenarios1,3
  • The oral bioavailability of CRESEMBA® is 98%, allowing for simple conversion between IV and oral administration1
Economic value of CRESEMBA®
  • CRESEMBA® is cost-effective relative to voriconazole for the treatment of invasive aspergillosis (based on a willingness-to-pay threshold of £30,000 per additional QALY)20
  • In patients with renal impairment, CRESEMBA® may reduce costs relative to voriconazole by significantly shortening the length of hospital stay for patients with invasive aspergillosis19
  • CRESEMBA® demonstrated a cost-saving of 36% per-patient treatment for mucormycosis relative to liposomal AmB + posaconazole21,d
d. The population included adult patients receiving primary treatment for mucormycosis. Dosing regimens were as per the respective Summary of Product Characteristics (liposomal AmB: 5 mg/kg; posaconazole – not indicated for mucormycosis: 3 x 100mg oral tablets/day, 600 mg loading dose).

Whether faced with invasive aspergillosis, or mucormycosis where amphotericin B is inappropriate, CRESEMBA® ensures that your patients are covered, and is also recommended by guidelines1,5-12

Which patients can CRESEMBA® help?
View patient profiles LoadingAE, adverse event; AmB, amphotericin B; BTK, Bruton’s tyrosine kinase; ESRD, end-stage renal disease; ITT, intent-to-treat; IV, intravenous; mITT, modified intent-to-treat; PK, pharmacokinetics; QALY, quality-adjusted life year; TEAE, treatment-emergent adverse event.Prescribing Information:

Click here for CRESEMBA® (isavuconazole) and Vfend (voriconazole) prescribing information

References:

1. CRESEMBA GB Summary of Product Characteristics.
2. Donnelley MA et al. Infect Drug Resist 2016;9:79–86.
3. Natesan SK and Chandrasekar PH. Infect Drug Resist 2016;9:291–300.
4. Perfect JR. Nat Rev Drug Discov 2017;16(9):603–616.
5. VFEND GB Summary of Product Characteristics.
6. Noxafil Summary of Product Characteristics.
7. Sporanox Summary of Product Characteristics.
8. Tissot F et al. Haematologica 2017;102(3):433–444.
9. Ullmann AJ et al. Clin Microbiol Infect 2018;24(Suppl. 1):e1–38.
10. Patterson TF et al. Clin Infect Dis 2016;63(4):e1–e60.
11. Cornely OA et al. Lancet Infect Dis 2019;19(12):e405–e421.
12. Cornely OA et al. Lancet Infect Dis 2019;19(12):e405–e421. (Appendix).
13. Maertens JA et al. Lancet 2016;387(10020):760–769.
14. Marty FM et al. Lancet Infect Dis 2016;16(7):828–837.
15. Groll AH et al. Clin Pharmacol Drug Dev 2017;6(1):76–85.
16. Wilson DT et al. Ther Clin Risk Manag 2016;12:1197–1206.
17. Cummins KC et al. Leuk Lymphoma 2019;60(2):527–530.
18. Perfect JR et al. Mycoses 2018;61(7):420–429.
19. Horn D et al. J Med Econ 2016;19(7):728–734.
20. Floros L et al. J Med Econ 2020;23(1):86–97
21. Bagshaw E et al. Future Microbiol 2017;12:515–525.
AboutLearn how CRESEMBA® allows for simple and reliable dosing Dosing information Loading Get more information about the economic value of CRESEMBA® Watch now Loading
PP-CRB-GBR-1777. March 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​